An observational study in Periodontal Disease, Staging, Salivary Markers, Diagnosis, sponsored by Midwestern University. Completed at 1 site in United States. Open to participants aged 30 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Midwestern University · Observational
The swelling of the gum, or periodontitis, is the leading cause for tooth loss, and currently affects up to 65 million adults only in the United States. One of the reasons for the widespread of periodontitis is because currently there are no definitive methods to detect the onset of gum disease. This lack of foresight impedes medical professionals to enact any preventive measures before the disease already manifests itself.
We wish to expand our understanding towards the development of periodontitis by studying the expression and activity of salivary markers that have been associated with advanced stages of the disease, wherein the supporting tissues of tooth (periodontium) are already irreversibly destroyed. We hypothesize that a progressive shift in the expression of such salivary markers can indicate a change or evolution of periodontitis staging.
In specific, we seek to establish a quantifiable relationship among levels of salivary proteases called MMPs, level of metal ions in different stages varying from health to periodontitis. The overall goal of this proposal is to enhance the predictability of periodontitis, as we are currently unable to diagnose the disease until the manifestation of its clinical signs and symptoms.
There is an urgent need for an efficient system to diagnose periodontal disease in its early stages. A recent investigation on the prevalence of periodontitis in adults living in the USA revealed that almost 50% of the assayed individuals had periodontal disease. Research on the economic burden of oral diseases estimated that productivity losses due to severe periodontitis and, consequently, due to tooth loss in North America (US and Canada) amounted US$ 116 billion yearly. This pervasiveness of periodontitis can be attributed to the conventional method of diagnosis, which is entirely based upon recognizing observable signs - an assessment of the disease's history.
A crucial restraint of these observable parameters is that they do not detect present disease activity and, therefore, cannot provide a real-time evaluation of the disease status. The lack of evidence-based knowledge regarding periodontal diseases activity and level of progression may ultimately lead to unintentional clinical mismanagement [6]. Accordingly, there is an unmet requisite for easy and readily available methods to herald the periodontium health condition prior to the manifestation of disease clinical signs [7].
Periodontal diseases are identified as being resultant from an inflammatory, host-mediated response, associated with dysbiotic plaque biofilms. Within the inflammatory host response of periodontal diseases there is a group of enzymes that are key, the matrix metalloproteinases (MMP). The abundance of MMPs, more specifically MMP-8, in saliva of individuals with severe periodontitis has shown to be high. In physiological conditions, the activity of MMPs is tightly controlled by changes in the balance between their expression and the expression of their major tissue endogenous inhibitors, called TIMPs. In addition, the catalytic competence of MMPs is highly dependent on the concentration of specific metal ions, zinc and calcium, which justifies the use of the prefix "metal" to classify and group this proteinase superfamily. As MMP-inhibitory medication has been shown to reduce the levels of MMPs in oral fluids, we hypothesize that collection of oral fluid samples (i.e., saliva and/or gingival crevicular fluid) from individuals appertaining to different stages of periodontal diseases can identify a shift in the balance between MMPs and their tissue-regulatory factors.
The overall objective of this proposal is to contribute to enhance the predictability of periodontitis and identify a method to heralding its onset. We hypothesize that the levels of salivary MMPs and other factors modulating these enzymes activity relate with different clinical stages of periodontal disease. The questions this research will address are: Do the level of MMPs vary as a function of periodontium health state? Is there a quantifiable relationship between salivary MMPs and other markers, such as MMP-Tissue Inhibitors (TIMPs) and metal ions, in the context of periodontitis?
Thus, the specific aims of this purposed study are:
867 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.
This study's enrollment of 106 is close to the median of 99 across 302 observational studies indexed under Periodontal Diseases.
Browse Periodontal Diseases studies →Midwestern University is the lead sponsor of 20 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The literature does not display a consistent number of estimate participants for reliable assessment of salivary markers; with correlate studies reporting to have included from 100 to 1000 participants. We aim to invite up to 200 subjects to participate in this research. Subjects will be allocated into four categories following the four stages of periodontitis from AAP classification, plus a fifth category as periodontal health individuals for control group. The results of this cohort will be analyzed to detect an effect size of 0.5 at the 0.05 significance level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals included in this cohort, other than meet the eligibility criteria, should present no clinical sign of periodontal disease. We anticipate to find from a very small number to none participants at this cohort. No intervention are anticipated.
Other: This is an observational study, no intervention is anticipated.
Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage I according to the American Academy of Periodontology. We anticipate low to moderate number of participants in this cohort. No interventions are anticipated.
Other: This is an observational study, no intervention is anticipated.
Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage II according to the American Academy of Periodontology. We anticipate a moderate number of participants in this cohort. No interventions are anticipated.
Other: This is an observational study, no intervention is anticipated.
Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage III according to the American Academy of Periodontology. We anticipate moderate to high number of participants in this cohort. No interventions are anticipated.
Other: This is an observational study, no intervention is anticipated.
Individuals included in this cohort, other than meet the eligibility criteria, should present clinical sign of periodontal defined as Stage IV according to the American Academy of Periodontology. We anticipate low to moderate number of participants in this cohort. No interventions are anticipated.
Other: This is an observational study, no intervention is anticipated.
There is no intervention. This is an observational study.
Matrix Metalloproteases (MMPs) Salivary Levels
Levels of MMPs assessed by different immuno-assays.
Time frame: October 2024
Levels of Metal Ions
Levels of metal ions assessed by Inductively Coupled Plasma Dynamic Reaction Cell Mass Spectrometer
Time frame: October 2024
Potential Correlation of MMPs, Metal Ions and Peridontitis Staging
The relationship between salivary MMPs and identified metal ions for all cohorts (periodontally healthy and periodontitis-affected individuals) will be determined by multiple regression analyses.
Time frame: October 2024
Plan to share: No — Individual participant data (IPD) will not make available to other researchers.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Midwestern University